Abstract
Background
Bone health may be impaired in children with epilepsy.
Objectives
Our objective was to characterize bone mineral density (BMD) and bone growth in children receiving antiepileptic drugs (AEDs) and to assess the effects of co-morbidity, vitamin D deficiency, and type of drugs used.
Data sources
Data were sourced from PubMed, Embase, and Web of Science.
Eligibility criteria
Cross-sectional, cohort, case-control, or randomized controlled trials reporting BMD or parameters of bone growth.
Participants
Children with epilepsy compared with controls.
Interventions
AEDS or ketogenic diet.
Study appraisal
The studies were evaluated by one author.
Synthesis methods
Studies were categorized as reporting reduced BMD or not at any skeletal site as outcome. A logistic regression was performed for age, percent boys, study design, type of AED, co-morbidity or not, and signs of vitamin D deficiency/osteomalacia or not.
Results
Carbamazepine and valproate were analyzed as monotherapy in 11 studies, and for both drugs a limited decrease in BMD seemed present. For oxcarbazepine, levetiracetam, phenytoin, phenobarbital, and topiramate, only one study with monotherapy was found for each drug, none of which reported decreased bone density. Polytherapy with AEDs seemed to be associated with a larger decrease in bone density than was monotherapy. Although few studies were available on bone growth, these did indicate that bone growth may be impaired among users of AEDs. Ketogenic diet may be associated with decreased bone density. The main determinant of normal BMD was absence of vitamin D deficiency/osteomalacia.
Limitations
The studies differed in skeletal sites studied and most were cross-sectional. No head-to-head comparisons of AEDs were performed. Children treated with polytherapy or ketogenic diet may have more complicated and severe disease than those treated with monotherapy. The underlying cause of epilepsy and vitamin D deficiency may contribute to impaired bone growth and density.
Conclusions
Reduced bone density, impaired bone growth, and vitamin D deficiency may be seen in children treated with drugs against epilepsy.
Implications
Measures to correct vitamin D deficiency, calcium intake should be taken.
Similar content being viewed by others
References
Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of anti-epileptic drugs. Epilepsia. 2004;45:1330–7.
Vestergaard P. Epilepsy, osteoporosis and fracture risk: a meta-analysis. Acta Neurol Scand. 2005;112:277–86.
Takahashi A, Onodera K, Shinoda H, et al. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn J Pharmacol. 2000;82:82–4.
Blake G, Adams J, Bishop N. DXA in adults and children. In: Rosen C, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Ames: Wiley; 2014. pp. 249–263.
Glüer C. Quantitative computed tomography in children and adults. In: Rosen C, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Ames: Wiley; 2014. pp. 264–276.
Blake G, Wahner H, Fogelman I. The evaluation of osteoporosis: dual energy X-ray absorptiometry and ultrasound in clinical practice. London: Martin Dunitz; 1999.
Gissel T, Poulsen C, Vestergaard P. Adverse effects of antiepileptic drugs on bone mineral density in children. Expert Opin Drug Saf. 2007;6:267–78.
Roende G, Ravn K, Fuglsang K, et al. DXA measurements in Rett syndrome reveal small bones with low bone mass. J Bone Miner Res. 2011;26:2280–6.
Leslie W, Adler R, El Hajj FG, et al. Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. J Clin Densitom. 2006;9:22–30.
Majumdar S. Magnetic resonance imaging of bone. In: Rosen C, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Ames: Wiley; 2014. pp. 277–282.
Forwood M. Growing a healthy skeleton: the importance of mechanical loading. In: Rosen C, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Ames: Wiley; 2014. pp. 149–155.
Norris S, Micklesfield L, Pettifor J. Ethnic differences in bone acquisition. In: Rosen C, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Ames: Wiley; 2014. pp. 135–141.
Yang T, Grover M, Joeng K, et al. Human fetal and neonatal bone development. In: Rosen C, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Ames: Wiley; 2014. pp. 119–126.
Wang Q, Seeman E. Skeletal growth and peak bone strength. In: Rosen C, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Ames: Wiley; 2014. pp. 127–134.
Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol. 2012;8:379–89.
Akin R, Okutan V, Sarici U, et al. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol. 1998;19:129–31.
Aksoy A, Sönmez FM, Deger O, et al. The effects of antiepileptic drugs on the relationships between leptin levels and bone turnover in prepubertal children with epilepsy. J Pediatr Endocrinol Metab. 2011;24:703–8.
Babayigit A, Dirik E, Bober E, et al. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol. 2006;35:177–81.
Cansu A, Yesilkaya E, Serdaroğlu A, et al. Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol. 2008;39:266–71.
Chou I, Lin K, Wang H, et al. Evaluation of bone mineral density in children receiving carbamazepine or valproate monotherapy. Acta Paediatr Taiwan. 2007;48:317–22.
Chung S, Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Develop. 1994;16:382–85.
Coppola G, Verrotti A, Mainolfi C, et al. Bone mineral density in angelman syndrome. Pediatr Neurol. 2007;37:411–6.
Ecevit C, Aydoğan A, Kavakli T, et al. Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol. 2004;31:279–82.
Erbayat AE, Serdaroglu A, Tumer L, et al. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab. 2001;13:933–9.
Farhat G, Yamout B, Mikati M, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 2002;58:1348–53.
El-Hajj Fuleihan G, Dib L, Yamout B, et al. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone. 2008; 43:149–55.
Gniatkowska-Nowakowska A. Fractures in epilepsy children. Seizure. 2010;19:324–5.
Guo C, Ronen G, Atkinson S. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia. 2001;42:1141–7.
Hahn TJ, Halstead LR, DeVivo DC. Disordered mineral metabolism produced by ketogenic diet therapy. Calcif Tissue Int. 1979;28:17–22.
Kafali G, Erselcan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila). 1999;38:93–8.
Koo DL, Joo EY, Kim D, et al. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res. 2013;104:134–9.
Kumandas S, Koklu E, Gümüs H, et al. Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J Pediatr Endocrinol Metab. 2006;19:529–34.
Lambrinoudaki I, Kaparos G, Armeni E, et al. BsmI vitamin D receptor’s polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy. Eur J Neurol. 2011;18:93–8.
Mikati MA, Dib L, Yamout B, et al. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology. 2006;67:2005–14.
Oner N, Kaya M, Karasalihoglu S, et al. Bone mineral metabolism changes in epileptic children receiving valproic acid. J Paediatr Child Health. 2004;40:470–3.
Phabphal K, Limapichat K, Sathirapanya P, et al. Bone mineral density following long-term use of antiepileptic drugs in a tropical Asian country. Epileptic Disord. 2008;10:213–8.
Phabphal K, Geater A, Limapichart K, et al. The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin. Epilepsia. 2013;54:249–55.
Rieger-Wettengl G, Tutlewski B, Stabrey A, et al. Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine. Pediatrics. 2001;108:E107.
Sheth R, Wesolowski C, Jacob J, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr. 1995;127:256–62.
Sheth RD, Hermann BP. Bone in idiopathic and symptomatic epilepsy. Epilepsy Res. 2008;78:71–6.
Sheth RD, Binkley N, Hermann BP. Progressive bone deficit in epilepsy. Neurology. 2008;70:170–6.
Sheth RD, Binkley N, Hermann BP. Gender differences in bone mineral density in epilepsy. Epilepsia. 2008;49:125–31.
Suzuki K, Ueda S, Umezu R, et al. Evaluation of bone mineral density using digital image processing in children receiving anticonvulsants. No To Hattatsu. 2007;39:351–5.
Tekgul H, Dizdarer G, Demir N, et al. Antiepileptic drug-induced osteopenia in ambulatory epileptic children receiving a standard vitamin D3 supplement. J Pediatr Endocrinol Metab. 2005;18:585–8.
Timperlake R, Cook S, Thomas K, et al. Effects of anticonvulsant drug therapy on bone mineral density in a pediatric population. J pediatr Orthop. 1988;8:467–70.
Tsukahara H, Kimura K, Todoroki Y, et al. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int. 2002;44:247–53.
Zhang J, Wang K, Wei Y, et al. Effect of topiramate and carbamazepine on bone metabolism in children with epilepsy. Zhongguo Dang Dai Er Ke Za Zhi. 2010;12:96–8.
Baer M, Kozlowski B, Blyler E, et al. Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status. Am J Clin Nutr. 1997;65:1042–51.
Onoe S, Mimaki T, Seino Y, et al. Delayed bone development in epileptic children assessed by microdensitometer. Dev Pharmacol Ther. 1988;11:24–31.
Lee H, Wang S, Salter DM, et al. The impact of the use of antiepileptic drugs on the growth of children. BMC Pediatr. 2013;13:211.
Barden HS, Smith E. Bone mineral in mentally retarded patients receiving long-term anticonvulsive therapy. Growth. 1975;39:371–88.
Coppola G, Fortunato D, Mainolfi C, et al. Bone mineral density in a population of children and adolescents with cerebral palsy and mental retardation with or without epilepsy. Epilepsia. 2012;53:2172–7.
Wietholtz H, Zysset T, Kreiten K, et al. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol. 1989;36:401–6.
Tjellesen L, Nilas L, Christiansen C. Does carbamazepine cause disturbances in calcium metabolism in epileptic patients? Acta Neurol Scand. 1983;68:13–9.
Mintzer S, Boppana P, Toguri J, et al. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia. 2006;47:510–5.
Larkin JG, McKee PJ, Forrest G, et al. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol. 1991;31:65–71.
Zerwekh J, Homan R, Tindall R, et al. Decreased serum 24,25-dihydroxyvitamin D concentration during long-term anticonvulsant therapy in adult epileptics. Ann Neurol. 1982;12:184–6.
Xiao D, Chen Y, Yang D, et al. Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation. Biochem Pharmacol. 2012;84:232–9.
Verrotti A, Coppola G, Parisi P, et al. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg. 2010;112:1–10.
Christiansen C, Rodbro P, Lund M. Effect of vitamin D on bone mineral mass in normal subjects and in epileptic patients on anticonvulsants: a controlled therapeutic trial. BMJ. 1973;2:208–9.
Christiansen C, Rodbro P. Initial and maintenance dose of vitamin D2 in the treatment of anticonvulsant osteomalacia. Acta Neurol Scand. 1974;50:631–41.
Bergqvist AGC, Schall JI, Stallings VA, et al. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr. 2008;88:1678–84.
Bertoli S, Striuli L, Testolin G, et al. Nutritional status and bone mineral mass in children treated with ketogenic diet. Recenti Prog Med. 2002;93:671–5.
Bertoli S, Trentani C, Ferraris C, et al. Long-term effects of a ketogenic diet on body composition and bone mineralization in GLUT-1 deficiency syndrome: a case series. Nutrition. 2014;30:726–8.
Verrotti A, Agostinelli S, Coppola G, et al. A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy. Eur J Neurol. 2010;17:232–7.
Ranganathan L, Ramaratnam S. Vitamins for epilepsy. Cochrane Database Syst Rev. 2005;2:CD004304.
Pack AM. Treatment of epilepsy to optimize bone health. Curr Treat Options Neurol. 2011;13:346–54.
Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.
Leventis P, Kiely PDW. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scand J Rheumatol. 2009;38:149–53.
Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009;4:CD000227.
Beaudart C, Buckinx F, Rabenda V, et al. The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2014;99(11):4336–45.
Sebestyen JF, Srivastava T, Alon US. Bisphosphonates use in children. Clin Pediatr (Phila). 2012;51:1011–24.
Vestergaard P, Mosekilde L, Langdahl B. Fracture prevention in postmenopausal women. Clin Evid (Online). 2011; 2011:pii1109.
O’Donnell S, Cranney A, Wells G, et al. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006;(4):CD005326.
Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–65.
Acknowledgments
Professor Vestergaard has no conflicts of interest that are relevant to this review. No funding was received for the preparation of this review.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Vestergaard, P. Effects of Antiepileptic Drugs on Bone Health and Growth Potential in Children with Epilepsy. Pediatr Drugs 17, 141–150 (2015). https://doi.org/10.1007/s40272-014-0115-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40272-014-0115-z